Kisspeptin therapy is still an investigational idea, not an established treatment. Kisspeptin is a natural brain signal that tells the body to release reproductive hormones. Short clinical studies show it can raise luteinizing hormone (LH) and, in men, testosterone. But the FDA has not approved it for any medical use, and the agency's 2024 review of kisspeptin-10 found too little human safety data to support compounding it. If you are asking about low testosterone, fertility or libido, a clinician can work through options that already have an approved footing. Start with the questions below.
TL;DR
- Kisspeptin activates the pathway that triggers GnRH, then LH and FSH. The effect on LH is the stronger one.
- It is not FDA-approved for any indication in the US, and kisspeptin-10 sits in the FDA's Category 2 for compounding, the category for substances with significant safety concerns.
- Human studies are small and short. The longest continuous exposure reported was 24 hours, and repeated dosing can blunt the response.
- hCG is a different drug. It acts on the testes directly, and it has a long clinical record in men with hypogonadotropic hypogonadism. No head-to-head fertility trial against kisspeptin has been published.
- Your best next step is a documented hormone workup and a conversation with a licensed clinician.
Table of Contents
- What kisspeptin is and how it works
- What kisspeptin has been studied for
- How kisspeptin has been given in studies
- Kisspeptin for men: what the data say
- Kisspeptin versus hCG
- FDA status: approved, compounded and investigational
- Side effects and unknowns
- Questions to bring to a clinician
- How AirMedFit can help you prepare
- Our perspective
- FAQ
- Sources
What kisspeptin is and how it works
Kisspeptin is a neuropeptide encoded by the KISS1 gene. It binds a receptor (KISS1R) on GnRH neurons in the hypothalamus. Those neurons control the pulses and surges of gonadotropin-releasing hormone, which in turn tell the pituitary to release LH and FSH. A 2022 review in the Journal of Neuroendocrinology describes this chain and notes that in humans kisspeptin stimulates both hormones, with a more marked effect on LH.
That position is why you see kisspeptin called a "master switch" of reproduction in popular articles. The description is a fair shorthand for its upstream role. It does not mean that giving the peptide is a proven way to restart or improve a hormone system. Whether an injected dose works as a therapy depends on dose, timing, formulation and the patient, and those are the points still unsettled.
A useful comparison: when researchers gave healthy men GnRH directly by vein, the response of LH and FSH was larger than after kisspeptin-10 or kisspeptin-54, by roughly three-fold for LH and two-fold for FSH. Kisspeptin works one step earlier in the chain, and it depends on the rest of the chain being intact.
What kisspeptin has been studied for
Researchers have looked at kisspeptin in a long list of reproductive conditions. A 2025 review names idiopathic hypogonadotropic hypogonadism, hyperprolactinemia, primary ovarian insufficiency, PCOS, endometriosis, hypothalamic amenorrhea, male-factor infertility and IVF. In these studies kisspeptin raised gonadotropins and, in some IVF work, helped trigger oocyte maturation. The same review states that therapeutic protocols have not been established.
Two findings show how much is still being learned:
- Diagnostic signal. In a cohort of children with delayed puberty, those whose LH rose by at least 0.8 mIU/ml after kisspeptin all went on to progress through puberty (8 of 8), while those with a response of 0.4 or less did not (8 of 8). That suggests kisspeptin may work as a test of how ready the system is, a different job from treatment.
- Possible opposite use. Because repeated exposure desensitizes the receptor, researchers have raised the idea that chronic kisspeptin could suppress the reproductive axis in hormone-dependent tumors such as prostate cancer. That is a hypothesis in the same 2025 review, and it shows why "more kisspeptin" is not simply "more hormones."
How kisspeptin has been given in studies
People often ask how kisspeptin is administered and what doses were used. Here the clinical record is narrow, and it comes from supervised research settings. This section describes what was published. It is not a dosing guide, and nothing here should be used to self-administer a peptide.
According to the FDA's October 2024 advisory committee briefing, kisspeptin has been given by intravenous bolus, intravenous infusion and subcutaneous injection in clinical studies. The reported IV bolus doses ranged from 0.31 to 13 mcg/kg, and infusions ran at up to 12.5 mcg/kg/h for 24 hours. A single subcutaneous bolus was tested in healthy adult women. Two Massachusetts General Hospital trials use a pump that gives pulsatile subcutaneous doses for two weeks. The FDA found no study that gave kisspeptin-10 to humans by the intramuscular route.

Earlier work set the pattern. The first human study, in 2005, used kisspeptin-54 in healthy men and produced dose-dependent LH increases during a 90-minute infusion. Kisspeptin-10 given as an IV bolus raised LH quickly, peaking about 30 minutes after a 1 mcg/kg dose, and a continuous infusion at 4 mcg/kg/h raised LH secretion four-fold.
Three things matter if you read these numbers:
- The doses are weight-based and were given under monitoring, often by vein. They do not translate into a vial, a syringe and a schedule at home.
- Different kisspeptin forms (kisspeptin-10, kisspeptin-54, long-acting analogs) behave differently, so doses cannot be swapped between them.
- Study length is the limit. The FDA found no published chronic fixed-schedule study that went beyond one day.
Kisspeptin for men: what the data say
Searches about kisspeptin in men usually come down to testosterone, libido and fertility. The evidence supports one narrow statement: kisspeptin acutely raises LH and testosterone in healthy men and in men with hypogonadotropic hypogonadism whose hypothalamic function is preserved. The FDA review puts the limits right next to that finding. It found no studies of adverse events at the doses and frequencies that would apply when treating men with reproductive disorders, and it found too little evidence to conclude kisspeptin is effective in men with secondary hypogonadism.
Here is what else the literature shows:
- A healthy-man response. In a dose-ranging study published in 2011, kisspeptin-10 boluses evoked LH secretion in men, and continuous infusion increased testosterone, LH pulse frequency and pulse size. The effect was real, but it was measured over hours.
- A lack of response in congenital disease. In people with congenital hypogonadotropic hypogonadism, LH did not rise after one or several kisspeptin boluses, across several genotypes. Kisspeptin needs working GnRH neurons downstream.
- A long-acting analog that did not hold up. The FDA review notes that the analog TAK-448 failed to maintain testosterone in the normal range in a Phase 2 trial, which ended in December 2016.
- Desensitization. Repeated or continuous administration can cause tachyphylaxis, which lowers gonadotropin and sex steroid levels. This has been seen in humans and animals after both IV and subcutaneous dosing.
In short, the acute hormone response is well described. A durable, safe treatment schedule for men has not been shown.
Kisspeptin versus hCG
Men comparing the two are usually asking the same underlying question: how do I raise testosterone or support sperm production without shutting down my own system? They are different tools aimed at different points in the pathway.
| Feature | Kisspeptin | hCG |
|---|---|---|
| Where it acts | Hypothalamus, to trigger GnRH release | Testes, through the LH receptor, mimicking LH |
| Dependence on the pituitary | Needs working GnRH neurons and pituitary | Bypasses the hypothalamus and pituitary |
| FDA status for men | Not approved for any indication | Approved in selected cases of hypogonadotropic hypogonadism in males |
| Human experience | Short studies, about 300 subjects estimated by the FDA | Long clinical use with documented fertility outcomes |
| Outcome data on sperm or pregnancy | No published fertility-endpoint trial against hCG | Retrospective and clinical series report spermatogenesis |
| Compounding in the US | Kisspeptin-10 in Category 2 of the 503A list | Handled as a prescription drug under clinician oversight |
Some of those rows deserve a source. The FDA labeling for chorionic gonadotropin products such as Novarel and Pregnyl includes selected cases of hypogonadotropic hypogonadism in males, as summarized in a coverage policy that lists the labeled indications. On fertility, a retrospective study of men with hypogonadotropic hypogonadism found spermatogenesis in 74% of patients on gonadotropin therapy, with higher success when FSH was added to hCG than with hCG alone, though only three men in that cohort received hCG by itself.
The practical read: for a man whose own hypothalamus and pituitary are working, kisspeptin might in theory prompt a pulse, but its effect fades with repeated use. hCG skips the upstream signal entirely. Which one fits, if any, is a decision for an endocrinologist or urologist who has seen your labs, and an approved product has a defined route to be prescribed. Kisspeptin does not.
FDA status: approved, compounded and investigational
These three words are not interchangeable, and they matter here.
- Approved means the FDA has reviewed a specific product for a specific use.
- Compounded means a licensed pharmacy prepares a drug from bulk ingredients for an individual patient. Federal rules limit which bulk substances can be used.
- Investigational means the substance is being studied and has not shown enough evidence of safety and effectiveness for approval.
Kisspeptin is investigational. The FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 11 no on adding kisspeptin-10 to the 503A bulks list in October 2024. The agency listed concerns about potential immunogenicity, peptide-related impurities, difficulty characterizing the active ingredient, and a lack of route-specific safety information. As of the April 22, 2026 category list, kisspeptin-10 remains in Category 2, which is for substances that raise significant safety concerns. The practical consequence is that kisspeptin is not available through FDA-compliant prescription or compounding channels in the US.
Products sold online as "research peptides" sit outside that system. A company registered with the FDA is not a company whose product has been approved. Registration of a facility says nothing about the identity, purity or safety of what it ships. Our guides on research peptide risks and how US patients can obtain peptides legally cover how to tell these categories apart.
Side effects and unknowns
In published short-term trials, the reported effects of kisspeptin include facial flushing (the most common), occasional nausea, injection site reactions, infrequent headache and rare abdominal discomfort. The FDA review found no serious adverse events attributed to kisspeptin in those trials. It also estimated that only about 300 people may have received kisspeptin-10 across the published studies, with possible overlap, and that many studies were small, brief and did not fully report adverse events.
The gaps are the heart of the matter:
- No chronic fixed-schedule study beyond one day. The longest repeated-bolus exposure was 11 hours in a day, and the longest infusion was 24 hours.
- No study built to measure anti-drug antibodies or immune responses.
- No data on adverse events at treatment-style doses in men with reproductive disorders.
- One adverse event report to the FDA described weight gain and a rise in estrone in a 17-year-old male after compounded subcutaneous use. The FDA judged it insufficient to establish cause, but it shows that off-label use is happening outside any monitored setting.
Anyone who is pregnant, trying to conceive, under 18, or living with a hormone-sensitive condition should talk to a licensed clinician before taking any hormone-active product, since these are the groups where an unmonitored hormone signal is most likely to cause harm.
Questions to bring to a clinician
If you landed here because of low energy, low libido, irregular cycles or fertility concerns, the useful move is to turn the question into data. A short list for your visit:
- What are my symptoms, and since when? Write the timeline down, including sleep, weight changes, medications and supplements.
- Which labs fit my situation? Total and free testosterone, LH, FSH, estradiol and prolactin are common starting points for men, and a clinician may add others.
- Is my picture primary (testes or ovaries), secondary (pituitary or hypothalamus), or neither?
- Is fertility a goal in the next year? That changes which options make sense, since some testosterone therapies reduce sperm production.
- Which options have FDA approval for my situation, and what does follow-up look like?
- Is there a clinical trial I could ask about? ClinicalTrials.gov lists the kisspeptin studies that are recruiting.
Bring prior lab results and a list of everything you take. That alone shortens the first visit.
How AirMedFit can help you prepare
Our site lists a Doctor's Consultation page, with an async option at 49 USD and a sync option at 120 USD, both one-off. Confirm current availability, scope and follow-up on the listing before you book. If you want baseline numbers before you talk to a clinician, the medical services collection lists Men's Essential lab panels at 129 USD and Women's Essential panels at 139 USD, each with a home kit included. Those panels are one-time purchases. For details on the consultation itself, see the consultation page.

If your underlying question is about testosterone or menopause hormone care, our TRT and HRT collection lists the Signature membership plans. We do not describe results or promise a prescription: any treatment decision is made by a qualified clinician after review of your history and labs.
Our perspective
Readers come to us asking about kisspeptin because they want a way to feel better and to get a hormone system working again. We understand that. The honest answer is that the interesting science and the available care are two separate things right now.
We think good hormone care starts with measurement. A clinician who can see your labs, your symptoms and your goals can tell you whether a problem sits in the brain, the pituitary or the gonads, and that answer decides what makes sense. That is why we build our content around consultation preparation, lab panels and clear conversations about approved options.
We also think you deserve a plain statement of how products are classified. Approved, compounded and investigational are not marketing categories, and the difference should be visible before you spend money. Our role is to help you ask better questions and to make the next step easy to find.
AirMedFit
FAQ
Is kisspeptin therapy FDA-approved?
No. Kisspeptin is not approved for any medical indication in the US. The FDA's advisory committee voted against adding kisspeptin-10 to the compounding bulks list, and it remains in Category 2. Clinical trials are the legitimate route to access.
What are the benefits of kisspeptin for men?
In research settings, kisspeptin acutely raised LH and testosterone in healthy men. That is a measured hormone response over hours, not a proven treatment benefit. The FDA found insufficient evidence of effectiveness in men with secondary hypogonadism.
Is kisspeptin better than hCG?
They are not interchangeable. hCG acts on the testes and has labeled use in selected cases of male hypogonadotropic hypogonadism. Kisspeptin acts upstream, is investigational, and no fertility-endpoint trial compares the two.
How is kisspeptin given in studies?
Trials have used IV bolus, IV infusion and subcutaneous injection, mostly for hours and under monitoring. The FDA found no human studies of kisspeptin-10 by the intramuscular route. Published dosing is not a basis for self-treatment.
Can kisspeptin affect fertility?
It stimulates the pathway that controls ovulation and sperm production, and it has been tested in IVF and infertility research. Repeated use can desensitize the receptor and lower hormone levels. A fertility specialist can discuss approved options.
Sources
- FDA, Pharmacy Compounding Advisory Committee briefing, October 29, 2024
- Invited review: Translating kisspeptin and neurokinin B, Journal of Neuroendocrinology, 2022
- Kisspeptins Regulating Fertility: Potential Future Therapies, 2025
- Review of human genetic and clinical studies of kisspeptin, 2021
- Kisspeptin-10 is a potent stimulator of LH in men, 2011
- Gonadotropins in male hypogonadotropic hypogonadism: spermatogenesis and fertility
- Human chorionic gonadotropin clinical policy bulletin, labeled indications
- ClinicalTrials.gov
Recommended
- Peptide Therapy Benefits: What's Proven and What Isn't
- Which Peptides Are FDA-Approved? A 2026 Guide
- 2026 FDA Review: How US Patients Can Obtain Peptides Legally
This article provides general educational information and is not personalized medical advice. A licensed clinician should assess treatment suitability, risks, and options.
